tHistone deacetylases(HDACs)are proteases that play a key role in chromosome structural modification and gene expression regulation,and the involvement of HDACs in can-cer,the nervous system,and the metabolic and immu...tHistone deacetylases(HDACs)are proteases that play a key role in chromosome structural modification and gene expression regulation,and the involvement of HDACs in can-cer,the nervous system,and the metabolic and immune system has been well reviewed.Our understanding of the function of HDACs in the vascular system has recently progressed,and a significant variety of HDAC inhibitors have been shown to be effective in the treatment of vascular diseases.However,few reviews have focused on the role of HDACs in the vascular sys-tem.In this study,the role of HDACs in the regulation of the vascular system mainly involving endothelial cells and vascular smooth muscle cells was discussed based on recent updates,and the role of HDACs in different vascular pathogenesis was summarized as well.Furthermore,the therapeutic effects and prospects of HDAC inhibitors were also addressed in this review.展开更多
As members of the immune checkpoint family, PD-1 and its ligand PD-L1 play critical roles in maintaining the balance between autoimmunity and tolerance. The interaction of PD-1/PD-L1 is also involved in tumor evasion ...As members of the immune checkpoint family, PD-1 and its ligand PD-L1 play critical roles in maintaining the balance between autoimmunity and tolerance. The interaction of PD-1/PD-L1 is also involved in tumor evasion inside the tumor microenvironment, caused by reduced T cell activation, proliferation, cytotoxic secretion, and survival. Previous research has shown that the expression level of PD-1/PD-L1 may be regulated by ubiquitin-mediated proteasome degradation, which is an important mode of post-translational modification (PTM). PD-1/PD-L1 ubiquitin modification research in tumor immunotherapy is the subject of the present review, which aims to assess the most recent developments in this area. We offer a short explanation of PD-1/PD-L1 as well as some basic background information on the UPS system and discuss many routes that target E3s and DUBs, respectively, in the regulation of PD-1/PD-L1 in tumor immunotherapy. In addition, we offer numerous innovative prospective research areas for the future, as well as novel immunotherapy concepts and ideas. Taken together, the information compiled herein should serve as a comprehensive repository of information about tumor immunotherapy that is currently available, and it should be useful in the design of future studies, as well as the development of potential targets and strategies for future tumor immunotherapy.展开更多
基金supported by the National Natural Science Foundation of China(No.82103508,82203758)Natural Science Foundation of Shaanxi Province(China)(No.SZYKJCYC-2023-028)+3 种基金the Science and Technology Development Incubation Fund of Shaanxi Provincial People's Hospital,Shaanxi,China(No.2021YJY-21)the Project of Tangdu Hospital,the Air Force Medical University,Shaanxi,China(No.XJSXYW202130,XJSXYW-2023015,2021LCYJ019)the Project of Air Foce Medical University,Shaanxi,China(No.2022LC2227)the Talent Support Program of Shaanxi Provincial People's Hospital,Shaanxi,China(No.2022JY-38).
文摘tHistone deacetylases(HDACs)are proteases that play a key role in chromosome structural modification and gene expression regulation,and the involvement of HDACs in can-cer,the nervous system,and the metabolic and immune system has been well reviewed.Our understanding of the function of HDACs in the vascular system has recently progressed,and a significant variety of HDAC inhibitors have been shown to be effective in the treatment of vascular diseases.However,few reviews have focused on the role of HDACs in the vascular sys-tem.In this study,the role of HDACs in the regulation of the vascular system mainly involving endothelial cells and vascular smooth muscle cells was discussed based on recent updates,and the role of HDACs in different vascular pathogenesis was summarized as well.Furthermore,the therapeutic effects and prospects of HDAC inhibitors were also addressed in this review.
基金supported by the National Natural Science Foundation of China(82103508,81871866,82173252)Shaanxi Special Support Plan-Program for Leading Talents of Science and Technology Innovation(China)(No.2019 Special Support Plan)+1 种基金the Natural Science Foundation of Shaanxi Province(China)(2016SF-308,2019SF-033,2022SF-145)Project of Tangdu Hospital,the Fourth Military Medical University(China)(No.2018 Key Talents).
文摘As members of the immune checkpoint family, PD-1 and its ligand PD-L1 play critical roles in maintaining the balance between autoimmunity and tolerance. The interaction of PD-1/PD-L1 is also involved in tumor evasion inside the tumor microenvironment, caused by reduced T cell activation, proliferation, cytotoxic secretion, and survival. Previous research has shown that the expression level of PD-1/PD-L1 may be regulated by ubiquitin-mediated proteasome degradation, which is an important mode of post-translational modification (PTM). PD-1/PD-L1 ubiquitin modification research in tumor immunotherapy is the subject of the present review, which aims to assess the most recent developments in this area. We offer a short explanation of PD-1/PD-L1 as well as some basic background information on the UPS system and discuss many routes that target E3s and DUBs, respectively, in the regulation of PD-1/PD-L1 in tumor immunotherapy. In addition, we offer numerous innovative prospective research areas for the future, as well as novel immunotherapy concepts and ideas. Taken together, the information compiled herein should serve as a comprehensive repository of information about tumor immunotherapy that is currently available, and it should be useful in the design of future studies, as well as the development of potential targets and strategies for future tumor immunotherapy.
